Compare AbbVie Inc (ABBV) vs Citigroup Inc. (C) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Citigroup (C) trades at $140.75, up 0.59% today, with a bullish technical outlook and strong analyst support. Recent Q1 2026 earnings beat expectations, and the company expanded its services by joining LPMCL. Revenue and net income have grown steadily, with a P/E of 17.78 and a consensus price target of $151.36. The stock is near its 52-week high, reflecting positive momentum.

The outlook is positive, driven by earnings growth and strategic expansions, but risks include volatile cash flows and high debt levels. Wall Street sentiment is bullish, with 59% of analysts rating it a buy. Investors should weigh the strong fundamentals against macroeconomic and operational risks.